NCT04512495 (SAMHY SARCOME) is a NA clinical trial of Blood samples will be collected at two times : in Sarcoma, sponsored by Institut Claudius Regaud.

Who is sponsoring NCT04512495?

NCT04512495 is sponsored by Institut Claudius Regaud.

What drugs are being tested in NCT04512495?

Interventions in NCT04512495: Blood samples will be collected at two times :.

Is NCT04512495 still recruiting?

NCT04512495 is currently completed. Last updated 10 December 2021.

Last reviewed 2021-12-10 · How we verify

NCT04512495: SAMHY SARCOME

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma?

Completed NA Last updated 10 December 2021

What this trial tests

NA trial testing Blood samples will be collected at two times : in Sarcoma in 60 participants. Completed in 2 December 2021.

Timeline

22 October 2020

Primary endpoint
2 December 2021

2 December 2021

Quick facts

Lead sponsor	Institut Claudius Regaud
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	60
Start date	22 October 2020
Primary completion	2 December 2021
Estimated completion	2 December 2021
Sites	1 location across France

Drugs / interventions tested

Blood samples will be collected at two times :

Conditions studied

Sarcoma — all drugs for Sarcoma →

Sponsor

Institut Claudius Regaud — full company profile →

Who can join

18 and older, any sex, with Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating "cancer cell/macrophage" hybrid cells in the peripheral blood. The study will be conducted on a population of patients with sarcoma and treated in the context of routine care. For each included patient, blood samples will be collected during baseline visit and after the initiation therapy. At the end of the 2nd blood collection, the patient will have completed his participation in the study.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice.
Agnoletto C, Caruso C, Garofalo C. · · 2021 · cited 12× · PMID 34063272 · DOI 10.3390/cancers13092189
Circulating Tumor Cells in Soft Tissue Sarcoma: Current Evidence and Clinical Implications.
Mendez-Guerra C, Chacon J, Altamirano IE, Calmet Rocca WR, et al · · 2026 · PMID 42192903 · DOI 10.3390/cancers18101542

Verify or expand the search:

Other recruiting trials for Sarcoma

Currently open trials in the same condition.

NCT07402577 — Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot · recruiting
NCT07501026 — Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC) · Phase 2 · recruiting
NCT07359911 — Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patient · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting

Other Institut Claudius Regaud trials

Trials by the same sponsor.

NCT07427186 — Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Early Stage · NA · not yet recruiting
NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
NCT06967961 — Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers · NA · recruiting
NCT06797037 — Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Pat · NA · recruiting
NCT06408038 — Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04512495 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Claudius Regaud
Last refreshed: 10 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04512495.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing